Literature DB >> 26876215

Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma.

Y-Y Jiang1, L Shang1, Z-Z Shi1, T-T Zhang1, S Ma1, C-C Lu2, Y Zhang1, J-J Hao1, C Shi1, F Shi1, X Xu1, Y Cai1, X-M Jia2, Q-M Zhan1, M-R Wang1.   

Abstract

Cell invasion and migration significantly contribute to tumor metastasis. Microtubule-associated protein 4 (MAP4) protein is one member of microtubule-associate proteins family. It is responsible for stabilization of microtubules by modulation of microtubule dynamics. However, there is little information about the involvement of MAP4 in human cancer. Here we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells. By activating the ERK-c-Jun-vascular endothelial growth factor A signaling pathway, MAP4 promotes cell invasion and migration in vitro, tumor growth and metastasis in mouse models. Immunohistochemical staining of operative tissues indicated that MAP4 expression was associated with tumor stage, lymph node metastasis and shorter survival of the patients with esophageal squamous cell carcinoma (ESCC). Multivariate Cox regression analysis showed that MAP4 is an independent prognostic indicator. In the serial sections of ESCC tissues, there was a positive correlation between MAP4 and vascular endothelial growth factor A expression. Notably, an intratumoral injection of MAP4-small interfering RNA (siRNA) remarkably inhibited the growth of the tumors that formed by the MAP4-expressing ESCC cells in nude mice, and a combination of MAP4-siRNA and Bevacizumab significantly enhanced the inhibition effect. Our data suggest that MAP4 is probably a useful prognostic biomarker and a potential therapeutic target for the disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26876215     DOI: 10.1038/onc.2016.17

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab.

Authors:  H X Chen; R E Gore-Langton; B D Cheson
Journal:  Oncology (Williston Park)       Date:  2001-08       Impact factor: 2.990

2.  Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma.

Authors:  Yan-Bin Feng; De-Chen Lin; Zhi-Zhou Shi; Xiao-Chun Wang; Xiao-Ming Shen; Yu Zhang; Xiao-Li Du; Man-Li Luo; Xin Xu; Ya-Ling Han; Yan Cai; Zi-Qiang Zhang; Qi-Min Zhan; Ming-Rong Wang
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

3.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein.

Authors:  M Murphy; A Hinman; A J Levine
Journal:  Genes Dev       Date:  1996-12-01       Impact factor: 11.361

4.  Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4.

Authors:  Brandon E Kremer; Timothy Haystead; Ian G Macara
Journal:  Mol Biol Cell       Date:  2005-08-10       Impact factor: 4.138

5.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

Authors:  H Gitay-Goren; S Soker; I Vlodavsky; G Neufeld
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

6.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

7.  Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.

Authors:  Wei-Jiunn Lee; Wen-Kang Chen; Chau-Jong Wang; Wea-Lung Lin; Tsui-Hwa Tseng
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-21       Impact factor: 4.219

8.  The p38/MAPK pathway regulates microtubule polymerization through phosphorylation of MAP4 and Op18 in hypoxic cells.

Authors:  Jiong-Yu Hu; Zhi-Gang Chu; Jian Han; Yong-ming Dang; Hong Yan; Qiong Zhang; Guang-ping Liang; Yue-Sheng Huang
Journal:  Cell Mol Life Sci       Date:  2009-11-14       Impact factor: 9.261

9.  Radiation-induced c-Jun activation depends on MEK1-ERK1/2 signaling pathway in microglial cells.

Authors:  Zhiyong Deng; Guangchao Sui; Paulo Mottin Rosa; Weiling Zhao
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

10.  Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer.

Authors:  Ibrahim Tekedereli; S Neslihan Alpay; Ugur Akar; Erkan Yuca; Cristian Ayugo-Rodriguez; He-Dong Han; Anil K Sood; Gabriel Lopez-Berestein; Bulent Ozpolat
Journal:  Mol Ther Nucleic Acids       Date:  2013-09-10       Impact factor: 10.183

View more
  13 in total

1.  Phosphatidylinositol-3-OH kinase signalling is spatially organized at endosomal compartments by microtubule-associated protein 4.

Authors:  Narendra Thapa; Mo Chen; Hudson T Horn; Suyong Choi; Tianmu Wen; Richard A Anderson
Journal:  Nat Cell Biol       Date:  2020-11-02       Impact factor: 28.824

2.  Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.

Authors:  Li-Ping Ge; Xi Jin; Yun-Song Yang; Xi-Yu Liu; Zhi-Ming Shao; Gen-Hong Di; Yi-Zhou Jiang
Journal:  Oncogene       Date:  2021-03-02       Impact factor: 9.867

3.  Human Papillomavirus 16 oncoprotein E7 retards mitotic progression by blocking Mps1-MAP4 signaling cascade.

Authors:  Yu Guo; Xiaojuan Zhang; Quanbin Xu; Fuxing Gong; Xiaoqian Shi; Chaokun Li; Rui Huang; Fangyuan Nie; Wen Zhu; Jiujie Li; Junbo Tang; Runting Li; Limeng Zhang; Longxin Chen; Runlin Z Ma
Journal:  Oncogene       Date:  2019-06-28       Impact factor: 9.867

4.  XBP1 induces MMP-9 expression to promote proliferation and invasion in human esophageal squamous cell carcinoma.

Authors:  Tian Xia; Song Tong; Kai Fan; Wei Zhai; Bin Fang; Si-Hua Wang; Jian-Jun Wang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

Review 5.  Susceptibility of cytoskeletal-associated proteins for tumor progression.

Authors:  Abiola Abdulrahman Ayanlaja; Xiaoliang Hong; Bo Cheng; Han Zhou; Kouminin Kanwore; Piniel Alphayo-Kambey; Lin Zhang; Chuanxi Tang; Muinat Moronke Adeyanju; Dianshuai Gao
Journal:  Cell Mol Life Sci       Date:  2021-12-29       Impact factor: 9.261

6.  Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation.

Authors:  Zhiqiang Ma; Chongxi Fan; Yang Yang; Shouyin Di; Wei Hu; Tian Li; Yifang Zhu; Jing Han; Zhenlong Xin; Guiling Wu; Jing Zhao; Xiaofei Li; Xiaolong Yan
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

Review 7.  Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells.

Authors:  Filip Borys; Ewa Joachimiak; Hanna Krawczyk; Hanna Fabczak
Journal:  Molecules       Date:  2020-08-14       Impact factor: 4.411

8.  Expression of Syk and MAP4 proteins in ovarian cancer.

Authors:  Siwei Zhang; Suha Deen; Sarah J Storr; Anqi Yao; Stewart G Martin
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-08       Impact factor: 4.553

9.  Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma.

Authors:  Xiaochun Xia; Chao He; Anqing Wu; Jundong Zhou; Jinchang Wu
Journal:  Dis Markers       Date:  2018-03-18       Impact factor: 3.434

10.  ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis.

Authors:  Sai Ma; Chen-Chen Lu; Li-Yan Yang; Juan-Juan Wang; Bo-Shi Wang; Hong-Qing Cai; Jia-Jie Hao; Xin Xu; Yan Cai; Yu Zhang; Ming-Rong Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.